.png)
TL;DRDrug supply shortage (Lieferengpass) is defined by the BfArM as a supply interruption of the usual delivery volume that is expected to last more than two weeks, or an unusually high demand that cannot be met adequately. It is a temporary, manufacturer-reported state, not a permanent withdrawal from the market.
The term matters because it is routinely confused with two neighbouring concepts, and the confusion has operational consequences. A drug supply shortage reported to the BfArM is not the same thing as a formally declared Versorgungsmangel, and neither is the same as an article being flagged as "außer Vertrieb" in the master data. Getting these three apart is the difference between a product you can substitute today and a product that has left the market for good.
Shortages arise for many reasons: a production problem at a single plant, a scarcity of the active ingredient, a sudden spike in demand, or a manufacturer withdrawing a pack. What they share is that the information you actually need in order to act, which product is affected, for how long, and what you can dispense instead, is spread across a report from the manufacturer and the article master data. Bringing those two sides together is the whole task.
All three describe a situation where a product is hard or impossible to obtain, but they sit at different levels: one is a manufacturer report, one is a ministerial declaration, and one is a distribution status. The table sets them apart.
| Concept | What it is | Who sets it | Legal basis |
|---|---|---|---|
| Drug supply shortage (Lieferengpass) | A supply interruption expected to exceed two weeks, or an unmet spike in demand. The product is still on the market, just not deliverable in the usual volume. | The pharmaceutical company, by self-report to the BfArM | Reporting duty under §52b AMG |
| Versorgungsmangel | A formally declared shortage that threatens supply, which unlocks regulatory exemptions such as permitting foreign-labelled packs. | The Bundesministerium für Gesundheit, by notice in the Bundesanzeiger | §79 Abs. 5 AMG |
| Außer Vertrieb | A distribution status in the article master data: the company has taken this pack out of distribution. It is a lasting state for that PZN, not a temporary bottleneck. | The pharmaceutical company, via the article data | Vertriebsstatus field, not a shortage report |
The practical reading: a drug supply shortage is a live signal that a substitution decision may be needed, a Versorgungsmangel is the state in which the rules for that substitution loosen, and "außer Vertrieb" tells you the specific pack is gone and you should look at the successor PZN rather than wait for it to return.
The reporting architecture is layered. It runs from a general duty for prescription medicines up to intensified obligations for the medicines the BfArM considers most important for supply.
The layering is deliberate. A general duty catches the bulk of prescription medicines, while the two escalating tiers concentrate the heaviest transparency requirements on the products whose failure would hurt most. For a supply or procurement team the practical takeaway is that the depth of official data behind a shortage tracks the classification of the medicine, and the most safety-critical products are also the best documented.
These duties feed the public BfArM shortage list, which is the register most professionals actually consult. That is exactly where a common misreading creeps in.
No. A BfArM shortage listing does not by itself prove that a patient cannot get the medicine. The list is built from the pharmaceutical companies' own reports, a self-declaration, and it records that one company cannot deliver one PZN in the usual volume. Other suppliers of the same active ingredient may be fully available, and a reported shortage is not the same as a shortage at the point of care.
Two readings help here. A drug supply shortage is a statement about one company's delivery capacity for one specific pack, keyed to its PZN. Whether a patient is actually affected depends on the wider picture: how many other manufacturers hold a marketing authorisation for the same active ingredient and strength, whether those alternatives are themselves reported, and whether a substitution is clinically appropriate. A single red line in a register answers only the first of those questions.
This is the misunderstanding that surfaces most often in practice: a listing is read as "the drug is gone", when it usually means "this one pack from this one manufacturer is constrained, and a substitution exists". The value is not in the listing alone. It is in what you can put next to it.
This is where owning the linked data beats a plain list. On pharmazie.com the daily BfArM shortage feed for Germany is not shown in isolation. Each shortage entry carries the reporting company, the shortage window with a start and expected end date, the reason, and a flag for hospital relevance. Next to that, the platform lists concrete substitute products drawn from the article master data, each with an available PZN, and where relevant it extends to EU and international alternatives. The shortage and its answer sit on one screen.
For the DACH market this matters twice over. A shortage in Germany can sometimes be answered by a product authorised in Austria or elsewhere in the EU, and the platform surfaces those international alternatives alongside the domestic ones, so a supply team is not restricted to the national article file when the national file has run dry.
That link, from a reported shortage to a specific, orderable alternative identified by PZN, is the part a plain shortage register does not give you. It turns a warning into a next step.
One honest limitation: a BfArM listing reflects the manufacturers' own reports, not a live warehouse feed. It tells you what companies have declared about their delivery capacity, not the real-time stock on a given wholesaler's shelf, so treat it as an early-warning and substitution layer rather than a guaranteed availability signal.
